Literature DB >> 17100755

Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles.

L D Carbone1, K J Warrington, K D Barrow, M Pugazhenthi, M A Watsky, G Somes, J Ingels, A E Postlethwaite.   

Abstract

A single infusion of pamidronate was given to patients with systemic sclerosis (scleroderma, SSc) to assess effects on cytokine production by peripheral blood mononuclear cells (PBMC) and lymphocyte subsets. Eighteen patients with SSc received a single intravenous dose of 60 mg of pamidronate and were followed for 6 months. Assessment of cytokine production [interferon (IFN)-gamma, interleukin (IL)-10, transforming growth factor (TGF)-beta1, tumour necrosis factor (TNF)-alpha and IL-4] by PBMC and lymphocyte subsets by flow cytometry was carried out before and after the pamidronate infusion. Unstimulated PBMC produced increased amounts of IFN-gamma and TNF-alpha and reduced levels of TGF-beta1 for up to 24 weeks after the infusion. gammadelta T cells from patients with SSc were activated in vitro and produced increased IFN-gamma. The effects of pamidronate on modulation of cytokine profiles in patients with SSc may merit future study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17100755      PMCID: PMC1810407          DOI: 10.1111/j.1365-2249.2006.03216.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  55 in total

1.  Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.

Authors:  V Kunzmann; E Bauer; J Feurle; F Weissinger; H P Tony; M Wilhelm
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

2.  TGF beta-like regulation of matrix metalloproteinases by anti-transforming growth factor-beta, and anti-transforming growth factor-beta 1 antibodies in dermal fibroblasts: Implications for wound healing.

Authors:  Neena Philips; Thomas Keller; Salvador Gonzalez
Journal:  Wound Repair Regen       Date:  2004 Jan-Feb       Impact factor: 3.617

Review 3.  Cytokine regulation of pulmonary fibrosis in scleroderma.

Authors:  Sergei P Atamas; Barbara White
Journal:  Cytokine Growth Factor Rev       Date:  2003-12       Impact factor: 7.638

4.  Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts.

Authors:  Kenichi Yamane; Hironobu Ihn; Yoshihide Asano; Masatoshi Jinnin; Kunihiko Tamaki
Journal:  J Immunol       Date:  2003-10-01       Impact factor: 5.422

5.  Human gamma/delta T-cell proliferation and IFN-gamma production induced by hexamethylene diisocyanate.

Authors:  Adam V Wisnewski; Christina A Herrick; Qing Liu; Liang Chen; Kim Bottomly; Carrie A Redlich
Journal:  J Allergy Clin Immunol       Date:  2003-09       Impact factor: 10.793

6.  Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers.

Authors:  Angela Del Rosso; Maura Boldrini; David D'Agostino; Giovanni Plinio Augusto Placidi; Alessandra Scarpato; Alberto Pignone; Sergio Generini; Yrio Konttinen; Massimo Zoppi; Tonko Vlak; Gianfranco Placidi; Marco Matucci-Cerinic
Journal:  Arthritis Rheum       Date:  2004-06-15

7.  Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

Authors:  R Eastell; I Barton; R A Hannon; A Chines; P Garnero; P D Delmas
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741

Review 8.  TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression.

Authors:  Franck Verrecchia; Alain Mauviel
Journal:  Cell Signal       Date:  2004-08       Impact factor: 4.315

9.  Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha.

Authors:  Carlo Chizzolini; Yann Parel; Carmelina De Luca; Alan Tyndall; Anita Akesson; Agneta Scheja; Jean-Michel Dayer
Journal:  Arthritis Rheum       Date:  2003-09

Review 10.  New insights into the molecular mechanisms of action of bisphosphonates.

Authors:  Michael J Rogers
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

View more
  12 in total

Review 1.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 2.  Scleroderma therapy: clinical overview of current trends and future perspective.

Authors:  Afsha A Topal; Rachita S Dhurat
Journal:  Rheumatol Int       Date:  2012-08-03       Impact factor: 2.631

3.  Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study.

Authors:  L Bondo; P Eiken; B Abrahamsen
Journal:  Osteoporos Int       Date:  2012-05-26       Impact factor: 4.507

4.  Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study.

Authors:  P N Sambrook; I D Cameron; J S Chen; L M March; J M Simpson; R G Cumming; M J Seibel
Journal:  Osteoporos Int       Date:  2010-10-20       Impact factor: 4.507

5.  Acute effects of intravenous administration of pamidronate in patients with osteoporosis.

Authors:  Mie Jin Lim; Seong Ryul Kwon; Shin-Goo Park; Won Park
Journal:  J Korean Med Sci       Date:  2010-08-14       Impact factor: 2.153

Review 6.  Pamidronate treatment in rheumatology practice: a comprehensive review.

Authors:  Gleb Slobodin; Itzhak Rosner; Joy Feld; Doron Rimar; Michael Rozenbaum; Nina Boulman; Majed Odeh
Journal:  Clin Rheumatol       Date:  2009-08-19       Impact factor: 2.980

Review 7.  Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.

Authors:  Ming Zhao; Jiali Wu; Haijing Wu; Amr H Sawalha; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-15       Impact factor: 8.667

8.  Letter to the editor: acute effects of intravenous administration of pamidronate in patients with osteoporosis.

Authors:  Annalisa Marcuzzi; Valentina Zanin; Josef Vuch; Alessandra Pontillo; Sergio Crovella
Journal:  J Korean Med Sci       Date:  2011-05-18       Impact factor: 2.153

9.  Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells.

Authors:  Sofia Sousa; Seppo Auriola; Jukka Mönkkönen; Jorma Määttä
Journal:  BMC Cancer       Date:  2015-01-15       Impact factor: 4.430

10.  Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations.

Authors:  Andréa Tavares Dantas; Sayonara Maria Calado Gonçalves; Anderson Rodrigues de Almeida; Rafaela Silva Guimarães Gonçalves; Maria Clara Pinheiro Duarte Sampaio; Kamila de Melo Vilar; Michelly Cristiny Pereira; Moacyr Jesus Barreto de Melo Rêgo; Ivan da Rocha Pitta; Claudia Diniz Lopes Marques; Angela Luzia Branco Pinto Duarte; Maira Galdino da Rocha Pitta
Journal:  Dis Markers       Date:  2016-11-14       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.